Key Findings
The Canada ophthalmic drugs market growth is set to project a CAGR of 7.39% during the forecast period, 2023-2030. The market growth is accredited to a growing aging population, increasing prevalence of eye disorders, and advancements in research and development.

Market Insights
Canadian research institutions and pharmaceutical companies actively engage in research and development endeavors aimed at discovering and creating innovative treatments for eye diseases. There is a growing emphasis on formulating personalized and precision medicine strategies tailored to meet the unique needs of individual patients. The nation boasts a robust healthcare system that provides access to specialized eye care services. Various facilities, including eye care clinics, ophthalmic hospitals, and private practices, offer an extensive range of services, spanning routine eye examinations to advanced surgical procedures.
Within Canada, Health Canada assumes the responsibility of regulating ophthalmic drugs. Manufacturers are required to comply with Good Manufacturing Practices (GMP) and meet the safety, efficacy, and quality standards established by Health Canada. The regulatory process involves a thorough evaluation of drug submissions, encompassing both new drug submissions (NDS) and abbreviated new drug submissions (ANDS) for generic products. This ensures that ophthalmic drugs fulfill the necessary criteria before being authorized for market distribution.
Nevertheless, the Canadian ophthalmology industry encounters challenges, including the high costs associated with drug development, regulatory approval processes, and limited access to specialized care in remote areas. Tackling these challenges offers opportunities for enhanced collaboration, the implementation of cost-effective solutions, and the integration of telemedicine to enhance accessibility to eye care services.

Competitive Insights
Pfizer Inc, Bausch Health Companies Inc, and Johnson & Johnson are among the prominent companies in the market.
Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments